With the acquisition, Abbott gains leadership in the $5.5 billion point-of-care segment, broadens its diagnostics footprint, and enhances access to fast-growing diagnostics channels.
This month's Product Spotlight features equipment, consumables, and labware from companies such as EKF Diagnostics, Olympus, Platinum Code, and Randox Laboratories.
This month's Product News includes focused gene expression panels, a cystatin C assay, a supply and procedure cart system, and a modular embedding system.
The company recently received ethical approval to commence a 6-month clinical study using its urine test for cancer.
Named Grail, the business seeks to enable early cancer detection via blood-based screening.
The assay was developed to offer confidence in patient results through standardization to the World Health Organization’s 3rd international standard for human thyroid stimulating hormone testing.
The line of labels is designed to stay secure on curved surfaces, including dishes, flasks, tubes, and vials.
The companies have partnered to develop a comprehensive next-generation sequencing workflow for single-cell analyses.
GenomeDx Biosciences recently presented first validation data supporting the use of its Decipher test to help guide the treatment of men newly diagnosed with prostate cancer.
The unit covers a temperature range of 4°C to 50°C to allow application flexibility.
Acquisition gives PE access to an innovative noninvasive prenatal testing solution under development, expanding the company’s maternal–fetal health portfolio.
The company reports that clinical trials using its MosaiQ transfusion diagnostic instrument and associated assays will begin later this year.
Lab managers and supervisors are given simplified remote access to their test utilization metrics.
The assay delivers cardiac troponin I results in about 15 minutes from either whole blood or plasma samples.
The recently FDA-cleared analyzer produces up to 900 photometric tests per hour and 1200 tests per hour when including electrolytes.
After closing $32 million in private equity financing, molecular diagnostics unit bioTheranostics will operate as an independent company.
Royal Philips and Banyan Biomarkers have entered into a multiyear agreement to jointly develop and commercialize a handheld blood test for detecting and evaluating mild traumatic brain injury.
Cepheid has signed a memorandum of understanding representing its intention to work with USAID to support the White House’s national action plan for combating MDR-TB.
The GeneStrat noninvasive, blood-based test is designed to provide accurate results in 72 hours for newly diagnosed non-small cell lung cancer patients.
Under a new collaboration agreement, NanoString will modify its PAM50-based Prosigna breast cancer assay for potential use as a companion diagnostic for enzalutamide treatment of triple-negative breast cancer.